Status:
UNKNOWN
Final Height in Patients With CAH
Lead Sponsor:
Ain Shams University
Conditions:
Congenital Adrenal Hyperplasia
Eligibility:
All Genders
Up to 18 years
Brief Summary
Congenital adrenal hyperplasia (CAH) is the most common inherited disorder in the adrenal gland in children. Growth is usually affected in CAH patients either due to the disease itself or treatment co...
Detailed Description
CAH comprises a group of autosomal recessive disorders caused by a deficiency of one of five enzymes needed for the synthesis of cortisol leading to defect in cortisol synthesis with or without aldost...
Eligibility Criteria
Inclusion
- Patients having a documented history of classical CAH.
Exclusion
- Patients with non classical CAH.
- Patients treated with growth hormone.
- Chronic use of medications unrelated to CAH which may affect growth like immunosuppressive drugs like azathioprine and drugs that affect growth hormone release like octreotide, pegvisomant, bromocriptine and cabergoline.
- Other chronic diseases that may affect growth like heart disease, inflammatory bowel disease and renal disease.
- Other causes of adrenal insufficiency.
Key Trial Info
Start Date :
March 11 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 11 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04293133
Start Date
March 11 2020
End Date
September 11 2020
Last Update
March 3 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.